Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma.

Raoul, Jean-Luc; Park, Joong-Won; Kang, Yoon-Koo; Finn, Richard S; Kim, Jun Suk; Yeo, Winnie; Polite, Blasé N; Chao, Yee; Walters, Ian; Baudelet, Christine; Lencioni, Riccardo

Raoul, Jean-Luc; Park, Joong-Won; Kang, Yoon-Koo; Finn, Richard S; Kim, Jun Suk; Yeo, Winnie; Polite, Blasé N; Chao, Yee; Walters, Ian; Baudelet, Christine; Lencioni, Riccardo.

Afiliación

Raoul JL; Département d'Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France.
Park JW; National Cancer Center, Goyang, Republic of Korea.
Kang YK; Asan Medical Center, Seoul, Republic of Korea.
Finn RS; Geffen School of Medicine, UCLA, Los Angeles, Calif., USA.
Kim JS; Korea University Guro Hospital, Seoul, Republic of Korea.
Yeo W; The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China.
Polite BN; The University of Chicago Medical Center, Chicago, Ill., USA.
Chao Y; Veterans General Hospital, Taiwan, Republic of China.
Walters I; Bristol-Myers Squibb, Princeton, N.J., USA.
Baudelet C; Bristol-Myers Squibb, Braine l'Alleud, Belgium.
Lencioni R; Pisa University Hospital, Pisa, Italy.

Liver Cancer ; 3(3-4): 439-50, 2014 Oct.

Article en En | MEDLINE | ID: mdl-26280005

Palabras clave

Alpha-fetoprotein; Brivanib; Hepatocellular carcinoma; WHO criteria; mRECIST

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Liver Cancer Año: 2014 Tipo del documento: Article País de afiliación: Francia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google